Gilead Sciences, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 18   

Articles published

GILD 74.15 -0.14 (-0.19%)
price chart
Navigating Biotech/Pharma Mergers and Acquisitions
Yao advises that those in nontraditional science jobs such as regulatory and manufactory should still be authors. On top of written communication, one also needs to know how to give good oral presentations.
China changes patent law in fight for cheaper drugs
HONG KONG China has overhauled parts of its intellectual property laws to allow its drug makers to make cheap copies of medicines still under patent protection in an initiative likely to unnerve foreign pharmaceutical companies.
Walk Test May Help Predict Cardio Risk
The 6-minute walk test may improve cardiovascular risk prediction in patients with stable coronary heart disease, researchers found.
Merck KGaA, Dr. Reddy's in biosimilars deal
FRANKFURT Germany's Merck KGaA and India's Dr. Reddy's Laboratories Ltd have struck a deal to develop cheap versions of biotech cancer drugs, seeking to tap into a new market as patents on biotech medicines expire.
Bay Area drugmakers telling Greeks to pay upfront
Genentech Inc., Gilead Sciences Inc., BioMarin Pharmaceutical Inc. and Bio-Rad Laboratories Inc. are among the companies waiting for millions of dollars from cash-strapped southern European countries, according to recent Securities and Exchange ...
Biomed Realty To Acquire Granta Park In Cambridge, UK For 126.8 Million Pounds ...
In addition, this premier life science research park is home to new tenants Gilead Sciences, Pharmaceutical Product Development, UCB, and Vernalis.
Foreseeing Risks Even When They're Beyond Control
“What is ultimately important is that that's communicated,” Robin Washington, CFO of Gilead Sciences told the CFO Network.
Top 10 Healthcare ETFs
The healthcare sector as a more defensive sector overall remains a positive holding in 2012 despite volatility in overall markets.
10 Best Vacation Cities for Beer Lovers
Gilead Sciences Advances Fatty Liver Drug for Reasons Causing Some Head Scratching · Jim Cramer -- Here's Why I Like Microsoft Ahead of ... �1996-2016 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.
Bristol-Myers Squibb (BMY) Acquires Amylin (AMLN) for $31/Share
(WLL) Misses Q2 EPS View By 14c · Glu Mobile (GLUU) Higher On EA's PopCap Game Purchase · Gilead Sciences (GILD) Estimates, PT Lowered at Baird · Beasley Broadcasting Group (BBGI) to Sell Four Charlotte-Area Radio Stations in $24M Deal (ETM).